Choose your location
LATEST NEWS
Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2024-- Nabla Bio (aka “Nabla”), pioneers in generative protein design, today announced the close of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZeneca, Bristol Myers Squibb Company and Takeda, worth more than $550 million in upfront and milestone payments, plus royalties. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514763517/en/ Nabla Bio Co-Founders Surge Biswas and Frances Anastassacos at the company’s labs in Cambridge, Mass. (Photo: Business Wire)
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
(Reuters) - Eisai and partner Biogen said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi.
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments. It’s essential to note our commitment to transparency: our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. We strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation. Join us in shaping the news narrative together.